94-186364/23 B05 NISE- 92.01.20
NIPPON SEIKA KK *JP 06122634-A
92.01.20 92JP-048124 *(94.05.06)* A61K 49/00, 9/127, 31/435, 31/505, 35/24, 49/04, 49/02, 43/00, 45/00, 47/26 // A61K 31/675, 31/70, 31/71, 33/24, 37/02

Diagnostic and therapeutic drugs for cancer - comprise liposome glucuronic acid- or galacturonic acid- binding glyco:lipid(s), as well as diagnostic drug images

C94-084556

Diagnostic drugs for cancer comprises liposome, contg. one or more kinds of glucuronic acid- or galacturonic acid-binding glycolipids, in which image diagnostic drugs are included.

Also claimed are therapeutic drugs for cancer comprising liposome, contg. one or more kinds of glucuronic acid- or galacturonic acid-binding glycolipids, in which cancer-treating drugs are included.

USE/ADVANTAGE - The agents are useful in diagnosis and therapy of cancer. Diagnosis with high sensitivity and also treatments of cancer with very limited adverse effects can be carried out by using these agents. Application of the liposome can avoid the intake of the drugs into reticulo-endothelial cells, thus leading to the selective distribution of the drugs in tumour tissues.

In an example, a mixt. of dipalmitoylphosphatidyl choline (80 micromoles), cholesterol (80 micromoles), hexadecyl beta-D-glucopyranosyluronic acid (40 micromoles), and (14)C-cholesterol oleate (30 micro-Ci) in 2:1 CHCl3-MeOH was conc. in a rotary evaporator. To the resulting film was added 0.8M glucose (1.25ml) contg. (3)H-inulin and the whole mixt. was stirred. The resulting emulsion was freeze-dried and then dissolved in water at 40 deg.C three times. The emulsion was passed through membrane filter of 0.12 micron and centrifuged. The deposit was suspended in 0.15M NaCl (3ml) to prepare a glycolipid-contg. liposome suspension (particle size 0.135 micron) for cancer diagnosis. (10pp Dwg.No.0/3)

B(4-C2V, 12-K4A1, 12-M11F, 14-H1)